SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-022091
Filing Date
2021-02-12
Accepted
2021-02-12 17:01:44
Documents
14
Period of Report
2021-02-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm216472d1_8k.htm   iXBRL 8-K 27273
2 EXHIBIT 10.1 tm216472d1_ex10-1.htm EX-10.1 145199
6 GRAPHIC image_001.jpg GRAPHIC 41214
  Complete submission text file 0001104659-21-022091.txt   441614

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nbrv-20210208.xsd EX-101.SCH 3184
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbrv-20210208_lab.xml EX-101.LAB 34592
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbrv-20210208_pre.xml EX-101.PRE 22709
7 EXTRACTED XBRL INSTANCE DOCUMENT tm216472d1_8k_htm.xml XML 3636
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 21629143
SIC: 2834 Pharmaceutical Preparations